Translate Promising Basic Biology Approaches that Target Drivers of Aging into Clinically Relevant, Regulatory-Compliant, Safe & Effective Drugs
For years, the promise of targeting the biology of aging has been held back by regulatory uncertainty, translational bottlenecks, and limited clinical validation. Now, with Eli Lilly joining NewLimit’s $45 million raise, valuing the biotech at roughly $1.6 billion, the momentum has reached a critical inflection point for age-related disease drug development.
Whether advancing senolytics, leveraging partial reprogramming, or repurposing proven drugs like GLP-1s, aging-targeted therapeutics are stepping out of the lab and into the clinic, and the next 12 months promise to be transformative.
This summit provides a dedicated platform to harness that momentum: learning from industry leaders such as BioAge Labs, Rubedo, Insilico Medicine and Halia Therapeutics; uncovering translational breakthroughs in models, biomarkers, and delivery; and exploring regulatory and investment strategies shaping the field.
Join 40+ biotech, pharma, and service provider experts driving the future of age-related disease therapeutics.
Really high calibre of presenters and excellent time management
Tesis Biosciences
Enjoyed the quality of speakers and the opportunity to network
Takeda
Breadth and depth of the presentations were outstanding
Cureline
Explore the Industry-Dedicated Agenda
- 40+ industry attendees
- 20+ world class speakers
- 5+ hours of dedicated networking
- 3 content-packed days from senior-level industry experts
- 2 interactive workshops with regulatory, C-suite, and investor insights
Attending Companies Include
Explore Related Events
Explore the Agenda
Dive into interactive workshops, investor panels, and case-study–led presentations to unlock exclusive insights into age-related disease drug development.
Partner With Us
Align your brand with pioneering biopharma leaders and place your preclinical models, biomarkers, and assays at the heart of a multi-billion-dollar market.
Connect With Age-Related Experts
Join dedicated networking hours and engage directly with C-suites, VPs of R&D, and translational heads driving first-in-human trials.